Read the source with the claim beside it
Here are the sources behind the linked statements. The notes say what each adds, so you can open the document that answers your question.
Match the source to the question
A medicine label gives its uses and warnings. A trial tells us what happened to a particular group. A review brings research together, but cannot fill in studies that haven’t been done.
When a finding sounds broad, look for who took part, what was compared and what changed. Those details tell us how far the result can travel. A result about a cream, for instance, cannot answer a question about an injection.
For regulatory wording, dates matter too. Body and treatment explains why a withdrawn nomination isn’t an approval. These links are for understanding the claims here; they don’t replace a personal medical assessment.
Medicine labels and human trials
Semaglutide prescribing information
The medicine’s actions and warnings, including the boxed thyroid warning.
DailyMed, US National Library of Medicine
Semaglutide in adults with overweight or obesity
Weight-management research with a placebo comparison and lifestyle support.
New England Journal of Medicine, 2021
Tirzepatide prescribing information
Stomach problems, the thyroid warning and the birth control interaction.
DailyMed, US National Library of Medicine
Tirzepatide in adults with obesity or overweight
Weight-management research in adults without diabetes, with a placebo comparison.
New England Journal of Medicine, 2022
Bremelanotide prescribing information
The narrow approved use, blood-pressure warning and cardiovascular restrictions.
DailyMed, US National Library of Medicine
Research with open questions
FDA’s assessment of BPC-157 evidence
Small human studies, missing comparisons and unanswered safety questions.
US FDA, July 2026
GHK biology and the reasons for research interest
Background biology; it does not establish benefits from an injection.
BioMed Research International, 2015
A review of topical GHK research
The shortage of studies in people using products applied to skin.
Bioimpacts, 2025
The notice withdrawing the former sermorelin approvals
The record ending the former approvals; read with the later finding.
Federal Register, 2009
FDA’s later determination about former sermorelin medicines
The later finding does not restore the withdrawn approvals.
Federal Register, 2013
A small study of hormone release in older men
A hormone rise without a change in body fat or muscle.
Metabolism, 1997
A review of sermorelin’s former specialist uses
Older safety observations, mostly from specialist studies involving children.
BioDrugs, 1999
NAD+ and cell metabolism
How NAD+ works in cells, rather than evidence for infusions.
Endocrine Reviews, 2010
Human evidence on NAD+ precursors and ageing
Blood readings do not establish health benefits; human evidence remains limited.
Nature Metabolism, 2025
A small retrospective report on infusion tolerability
Symptoms reported in one setting, without a reliable rate for everyone.
Frontiers in Aging, 2026
The route to legitimate care
FDA’s explanation of compounding
Why some patients need a medicine made for them.
US FDA
FDA on the risks of compounded medicines
What FDA has not reviewed before these medicines are marketed.
US FDA
FDA’s peptide safety concerns and withdrawn nominations
Withdrawn nominations still carry safety concerns, without individual withdrawal dates.
US FDA
HHS on permission to practise across state lines
How the patient’s location affects permission to practise online.
US Department of Health and Human Services
State medical boards and public licence records
Public licence and discipline records, with no guarantee of judgement.
Federation of State Medical Boards